ÂÜÀòÂÒÂ×

Beth J Hoffman has a diverse and impressive work experience in the biopharmaceutical industry. Beth J is currently serving as the CEO of Origami Therapeutics, Inc. since October 2015. Prior to that, they held the role of Vice President, Discovery Biology at Vertex Pharmaceuticals, Inc. from July 2007 to December 2014.

Before joining Vertex Pharmaceuticals, Inc., Beth worked at Amgen, Inc. as the Scientific Executive Director, Neuroscience from August 2004 to December 2006. During their time at Amgen, they built and guided a neuropsychiatric drug discovery group and was elected to the Scientific Advisory Board for Amgen Ventures.

Beth's earlier experience includes a tenure at Eli Lilly & Co, where they served as the Head of Neuroscience from September 1998 to July 2004. Beth J also worked at the National Institute of Mental Health as the Head of the Unit on Molecular Pharmacology from 1988 to 1998. During their time there, they established and directed a team focused on cloning neurotransmitter transporters and studying their role in synaptic physiology. Their contributions in this field earned their the Anna-Monika Foundation Prize in 1993 for advancements in knowledge about the biological substrate and functional disturbances of depression.

Additionally, Beth recently joined Biofrontera Inc. as a Member of the Board of Directors, starting in October 2021. This U.S.-based biopharmaceutical company specializes in photodynamic therapy and topical antibiotics.

Overall, Beth J Hoffman's work experience demonstrates their expertise and leadership in the biopharmaceutical industry, particularly in areas such as drug discovery, neuroscience, and molecular pharmacology.

Beth J Hoffman earned their A.B. in Molecular Biology from Wellesley College, where they studied from 1975 to 1979. Beth J further pursued their education at The Johns Hopkins University, where they obtained their Ph.D. in Molecular Pharmacology and Cell Biology. Their doctoral studies at The Johns Hopkins University spanned from 1983 to 1988.